Kaiser, Ulrike http://orcid.org/0000-0002-9701-9028
Liedgens, Hiltrud
Meissner, Winfried
Weinmann, Claudia
Zahn, Peter
Pogatzki-Zahn, Esther
Funding for this research was provided by:
Innovative Medicines Initiative (777500)
Article History
Received: 1 August 2019
Accepted: 9 August 2020
First Online: 10 September 2020
Ethics approval and consent to participate
: The methods and procedure of the study are developed in compliance with the ethical principles of the Helsinki Declaration and Good Epidemiologic Practice and have been approved by Ethical committee of TU Dresden (EK 261052019). The process is described as a consensus process including patients who are announced by official organizations (self-help organizations) and therefore represent the interests of those organizations. No treatment is offered and patients will not be harmed. All data of all participants will be gathered and analyzed completely anonymously and on a group level. No personal data will be gathered. Consent forms will be filled in by each participant in order to comply with consent and data security standards.
: EPZ: During the last 5 years, EPZ received financial support from Mundipharma and Grünenthal for research activities, advisory and/or lecture fees and travel support from Grünenthal, MSD Sharp & DOHME GmbH, Mundipharma GmbH; Mundipharma International; Janssen-Cilag GmbH; Fresenius Kabi and AcelRx.HL: Hiltrud Liedgens is an employee of Gruenenthal GmbHWM: Research: Pfizer, Grünenthal, Mundipharma. Advisory: Grünenthal, Tilray, Sanofi. Lecture fees: Grünenthal, Northern Swan, TAD, Kyowa, Bionorica.CW: NonePZ: NoneUK: Travel and accommodation refunds by Mundipharma and Gruenenthal